Answers are grounded in this paper and cite their sources.
For close to half a century one rule defined the antibody, two heavy chains and two light chains, so that every antigen-binding site is built from a paired heavy and light variable domain. Camelids break it. Camels, llamas, and alpacas circulate abundant heavy-chain-only antibodies (HCAbs), in which a single variable domain, the variable heavy-chain domain of an HCAb (VHH), binds antigen with no light-chain partner and no CH1 domain to hold one. A VHH, termed a nanobody as a standalone recombinant protein, is typically 12 to 15 kDa and among the smallest antigen-binding units reaching the clinic. This review reframes that stripped-down design not as something the HCAb lacks but as the source of what it can do, and keeps separate two mechanisms often merged into a single explanation. HCAbs use specialized germline gene segments encoding VHH domains with framework-2 substitutions at the position of the conventional VH–VL interface and extended complementarity-determining region 3 (CDR3) loops. Together with a splice-donor mutation that excludes the CH1 exon, these features enable secretion of HCAb homodimers whose VHH domains fold, remain soluble, and bind antigen autonomously. HCAbs are highly thermostable and reach enzyme active sites, cryptic pockets, and conserved viral surfaces inaccessible to conventional antibodies. We assemble the evidence that HCAbs are a working arm of camelid humoral immunity, drawing on dromedary, Bactrian, llama, and alpaca data on serum and secretory isotype composition, antigen-dependent recruitment of this arm, the epitopes VHH paratopes reach preferentially, retained Fc-mediated effector function, and the prenatal establishment of heavy-chain-committed B cells. We follow the architecture through the camelid heavy-chain locus and its alpaca-specific features ( Vicugna pacos ), and compare it with the single-domain receptors that sharks and lampreys arrived at independently. We then trace it into a diagnostic and imaging toolkit anchored by the first approved nanobody drugs, and into genome editing, where mice and rats already make HCAbs of their own, leaving one step unclaimed, building the trait back into the animals that evolved it. This minimalism still cannot explain how these B cells mature, compete, and are rendered tolerant. That is where the field should look next.
No takes yet. Share an insight, caveat, or question.
Landinez-Aponte et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: